Released : October 10, 2018 07:00 RNS Number : 4884D MaxCyte, Inc. 10 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Commences Dosing in First Clinical Trial in Solid Tumours First patient dosed in Phase I clinical study to evaluate MaxCyte's lead CAR therapeutic in
Released : October 08, 2018 07:00 RNS Number : 2057D MaxCyte, Inc. 08 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting Gaithersburg, MD - 08 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company
Released : September 24, 2018 07:00 RNS Number : 6299B MaxCyte, Inc. 24 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2018 Gaithersburg, Maryland - 24 September 2018 - MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and
Released : September 10, 2018 07:00 RNS Number : 2308A MaxCyte, Inc. 10 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 10 September 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the
Released : September 03, 2018 07:00 RNS Number : 4933Z MaxCyte, Inc. 03 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, MD - 03 September 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company , will
Released : July 26, 2018 17:33 RNS Number : 9375V MaxCyte, Inc. 26 July 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Person Closely Associated Dealing Maryland, USA , 26 July 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that
Released : July 16, 2018 07:00 RNS Number : 6677U MaxCyte, Inc. 16 July 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Programme Company to conduct Phase I clinical study of MCY-M11, a CAR therapeutic, in
Released : July 16, 2018 07:00 RNS Number : 6675U MaxCyte, Inc. 16 July 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Gaithersburg, Maryland - 16 July 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company , provides an update on
Released : June 11, 2018 07:00 RNS Number : 8631Q MaxCyte, Inc. 11 June 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte and U.S. National Institutes of Health's National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease
Released : May 21, 2018 07:00 RNS Number : 6263O MaxCyte, Inc. 21 May 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Correction of Sickle Cell Disease Mutation in Hematopoietic Stem Cells - Data demonstrate the
